CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jinjun Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, P.R. China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Receptors, Colony-Stimulating Factor, Mutation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Department of Sichuan Province, 1·3·5 Project for Disciplines of Excellence-Clinical Research Fund, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Background
Activating colony‐stimulating factor 3 receptor ( CSF3R ) mutations are uncommon in acute myeloid leukemia (AML), and their prognostic significance remains unclear.
Methods
We compared clinical, treatment response, and survival data between CSF3R ‐mutated and CSF3R ‐wild‐type AML patients.
Results
CSF3R ‐mutated cases presented a distinct molecular profile, with T618I and T640A being the most frequent variants. Common molecular aberrations included CEBPA bZip mutations (40%) and CBF fusions (23%), as well as secondary‐type AML‐associated mutations such as those in ASXL1 , SRSF2 , and EZH2 . In contrast, NPM1 mutations were significantly less common in CSF3R ‐mutated patients ( p = 0.03). Induction responses were poorer in CSF3R ‐mutated AML patients, with lower complete remission (55.6% vs. 78.8%, p = 0.004), reduced measurable residual disease (MRD) negativity (53.3% vs. 87.6%, p < 0.001), and shorter MRD maintenance duration (5.4 vs. 21.6 months, p < 0.001). According to the logistic regression analysis, CSF3R mutation emerged as an independent predictor of induction failure ( p < 0.001). Survival outcomes were also inferior: the median overall survival (OS) was 20.7 months versus not reached ( p = 0.0013), and progression‐free survival was 9.4 versus 63.6 months ( p < 0.0001). The adverse impact of CSF3R mutations was most pronounced in CEBPA bZip AML. CSF3R mutations abrogated the expected favorable prognosis (3‐year OS: 44.2% vs. 88.2%, p = 0.0008). Conversely, CSF3R status did not affect outcomes in CBF‐rearranged patients ( p = 0.70).
Conclusions
CSF3R mutations define a distinct, high‐risk AML subset characterized by an inferior treatment response and survival, warranting incorporation into future risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, P.R. China.
- Department of Dermatology, West China Hospital, Sichuan University, Chengdu, P.R. China.
ORCID-Profile: Jinjun Yang, Yu Wu, Hongbing Ma
Förderung
- Science and Technology Department of Sichuan Province
- 1·3·5 Project for Disciplines of Excellence-Clinical Research Fund, West China Hospital, Sichuan University
Zitieren
APA
Yang, J., Wang, L., Zhu, M., Xiang, X., Wu, Y., Niu, T., Gong, Y., Chen, X., He, C., Dai, Y., Shuai, X., & Ma, H. (2025). CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.71471
Vancouver
Yang J, Wang L, Zhu M, Xiang X, Wu Y, Niu T, et al. CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.71471
BibTeX
@article{Yang2025,
author = {Yang, Jinjun and Wang, Lian and Zhu, Min and Xiang, Xinrong and Wu, Yu and Niu, Ting and Gong, Yuping and Chen, Xinchuan and He, Chuan and Dai, Yang and Shuai, Xiao and Ma, Hongbing},
title = {CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71471}
}
EUVIMED